Study Evaluates Telomere and Mitochondrial Dysfunction in Pollutant-Induced Endothelial Senescence and Protective Effects of Astragaloside IV

Researchers reported that fine dust exposure accelerates telomere and mitochondrial senescence preferentially in endothelial cells rather than smooth muscle cells, a phenotype partially reversed by Astragaloside IV, showing cell-type-specific susceptibility in vascular aging.

A study published in Cardiovascular Toxicology investigated telomeric and mitochondrial alterations in human umbilical vein endothelial cells (HUVECs) and human coronary artery smooth muscle cells (hVSMCs) under replicative senescence and stress-induced premature senescence (SIPS).

Researchers induced SIPS using a 48-hour exposure to fine dust, a PM10-like reference material, at concentrations of 50 and 100 μg/mL, followed by a 24-hour treatment with 50 μM Astragaloside IV (AS-IV).

The fine dust exposure predominantly caused premature senescence, telomere shortening, TERRA upregulation, and acute mitochondrial impairment in HUVECs, whereas hVSMCs demonstrated relative resistance to these effects despite displaying telomere shortening.

Treatment with AS-IV partially attenuated the telomeric and mitochondrial damage in HUVECs but showed only limited efficacy in hVSMCs.

The findings establish that vascular aging under environmental stress is governed by cell-type-specific interactions between telomeres and mitochondria.

By identifying endothelial cells as highly susceptible to particulate-matter-induced senescence, the research localizes the primary site of environmental vascular damage.

The modest protective efficacy of Astragaloside IV in endothelial cells supports the feasibility of telomere- and mitochondria-targeted interventions to protect vascular integrity in polluted environments.

The demonstrated cell-type-specific susceptibility highlights a challenge for developers of systemic senolytics or senomorphics, suggesting that vascular-focused therapeutics may need to target endothelial-specific mechanisms.

This scientific evidence supports the broader development of mitochondrial and telomeric protective platforms, though clinical translation remains early-stage as no commercial candidates are currently evaluating Astragaloside IV for pollution-induced vascular aging.

Further preclinical studies validating the protective effects of Astragaloside IV or synthetic derivatives in live animal models of air pollution-induced cardiovascular disease.

Mechanistic research detailing the exact signaling pathway connecting the observed endothelial-specific telomere shortening with acute mitochondrial impairment.